Highlights

  • Pro Medicus (ASX:PME) reported FY26 underlying NPAT of A$144.7 million, up 24.1%, supported by higher Revenue and strong operating margins.
  • Revenue increased 22.9% to A$261.7 million, while the company secured A$548 million of new contract commitments.
  • The Visage platform continued to deliver high-margin growth, with underlying EBIT margin improving to 74.9%.
  • Investors are watching contract implementation, AI product development, valuation expectations and expansion into new healthcare imaging markets.

Pro Medicus (ASX:PME) delivered another year of strong operational growth, supported by rising revenue, major healthcare contracts and industry-leading software margins. The company continues to expand its position in medical imaging technology, while new opportunities in reporting, artificial intelligence and adjacent healthcare areas could broaden the Long-term Growth opportunity. However, the key debate for investors remains whether the company's premium valuation already reflects years of successful execution ahead.

Another record result, but profit figures require context

Pro Medicus reported FY26 results for the year ended 30 June 2026, showing continued growth across its core software business.

Statutory net profit increased significantly to approximately A$265 million.

However, the statutory figure was influenced by non-cash valuation gains on the company's Equity investments in other listed healthcare technology companies.

The more relevant measure of underlying operating performance was underlying NPAT of A$144.7 million, which increased 24.1%, or 32.5% on a currency-neutral basis.

The underlying result reflects the continued strength of Pro Medicus' core imaging software platform rather than investment-related accounting movements.

The engine: contract wins and future revenue visibility

Revenue increased 22.9% to A$261.7 million, with constant-currency growth of 28.4%.

The company's future growth profile was reinforced by significant contract activity during FY26.

Pro Medicus signed 10 new contracts with a minimum combined value of A$407 million.

The company also renewed six existing agreements at higher fees, adding a further A$141 million of commitments.

Together, these represented approximately A$548 million of new contract value.

Major customer wins included US healthcare systems such as UCHealth Colorado and Beth Israel Lahey Health, along with other healthcare institutions across North America and Europe.

Forward contracted revenue over five years increased 41.3% to approximately A$1.34 billion.

A key feature of the Business model is that many newly implemented systems contribute increasing transaction revenue over time as healthcare imaging volumes expand.

Software Economics remain a major strength

Pro Medicus' Visage platform continues to demonstrate attractive software characteristics.

The platform operates through a transaction-based model, where revenue increases as customer imaging volumes grow after implementation.

This structure supported an underlying EBIT margin of 74.9%, up from 74.0%.

Underlying EBIT increased 24.4% to A$196.1 million.

The Balance Sheet remained strong, with A$252.3 million in cash and financial Assets and no debt.

The board increased the full-year Dividend by 25.5% to 69 cents per share, fully franked.

The company's renewal record also remains notable, with all contracts due for renewal during the period renewed at higher fees.

This highlights the embedded nature of Visage within healthcare workflows and the high switching costs associated with replacing imaging infrastructure.

What is driving the stock

The Pro Medicus (ASX:PME) Investment case continues to be supported by three major themes.

The first is ongoing expansion in North America, which represents the majority of group revenue.

The second is the recurring nature of the platform, where installed systems can generate increasing revenue as customer usage grows.

The third is the development of artificial intelligence capabilities across medical imaging.

The company is increasingly positioning itself beyond image viewing toward a broader healthcare imaging ecosystem.

However, valuation remains the central debate.

Pro Medicus trades at a significant premium compared with many software companies, reflecting investor confidence in future growth.

That premium also means expectations are high.

Any slowdown in contract wins, implementation timing or revenue growth could result in increased share-price sensitivity.

The growth story: expanding from imaging viewer to healthcare platform

The medium-term opportunity is based on expanding the role of the Visage platform.

Visage 7 Reporting is expected to extend Pro Medicus further into radiology reporting workflows, creating additional revenue opportunities within existing customer relationships.

The company is also exploring adjacent areas including cardiology and digital pathology.

Artificial intelligence remains another potential growth avenue.

Pro Medicus is developing diagnostic AI capabilities, including a breast-cancer detection algorithm that is subject to regulatory approval.

The company's investments in healthcare technology businesses also provide potential exposure to complementary AI and imaging solutions.

The broader opportunity is to evolve from an imaging viewer provider into a more comprehensive medical-imaging technology platform.

If successful, this could increase both the addressable market and revenue generated per healthcare customer.

The risks: high expectations create limited room for error

The largest risk remains valuation.

A premium-priced growth company must continue delivering strong operational performance to justify expectations.

Contract wins can be uneven, and a slower period of new customer additions could affect market sentiment.

Customer concentration is another consideration, particularly given the importance of large US healthcare systems.

Healthcare spending cycles, regulatory changes and currency movements can also influence reported results.

Artificial intelligence presents both opportunity and risk.

While AI tools may expand Pro Medicus' capabilities, competing platforms developed by larger technology companies could challenge parts of the company's Competitive Advantage over time.

Regulatory approval timelines for AI-based healthcare products can also be unpredictable.

The company's reliance on experienced Leadership and a focused operating model remains another Factor investors will monitor as the business scales.

What Investors Should Watch Next

The February 2027 half-year result will provide the next major operational checkpoint.

Investors should monitor how quickly newly implemented systems begin contributing transaction revenue and whether contract momentum continues.

Other important areas include:

  • regulatory progress for AI-related healthcare products;
  • adoption of Visage 7 Reporting;
  • expansion into cardiology and digital pathology;
  • additional North American contract wins;
  • revenue growth and margin sustainability.

These factors will determine whether Pro Medicus can continue expanding at the pace required to support its valuation.

The Bottom Line

Pro Medicus (ASX:PME) delivered another strong FY26 performance, with higher revenue, expanding margins, significant contract wins and continued growth across its healthcare imaging platform.

The operating business remains one of the higher-quality technology stories on the ASX.

The challenge for investors is valuation.

The market is already pricing in continued execution, strong contract growth and successful expansion into AI-enabled healthcare solutions.

For Pro Medicus, the next phase will depend on converting its technology advantage, contract pipeline and AI opportunities into sustained Earnings growth.

The business continues to demonstrate quality, but expectations remain equally demanding.